Brought to you by 
Celgene and Juno partner in CART/TCR deal worth $1bn up front
16 Nov 2021
Executive Summary
Celgene Corp. and Juno Therapeutics Inc. entered into a major ten-year alliance that sees both partners benefiting from the other’s immunotherapeutics expertise, with an initial focus on T-cell receptor (TCR)- and chimeric antigen receptor T-cell (CART)-based treatments for cancer and autoimmune diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene and Juno partner in CART/TCR deal worth $1bn up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice